BiomX Inc. announced a one-for-nineteen reverse stock split of its common stock, which will trade on the NYSE American under the symbol “PHGE” starting November 25, 2025. The split was approved by stockholders at the 2025 Annual Meeting and will not change the par value or authorized number of shares. The number of outstanding shares will decrease to around 1,526,640 after the split, with adjustments made to equity awards and stock incentive plans. Fractional shares will be rounded up for stockholders, and instructions for exchanging shares will be provided by the transfer agent. For more details, visit www.biomx.com.

The reverse stock split by BiomX is expected to take effect on November 25, 2025, reducing outstanding shares to approximately 1,526,640. Stockholders will receive instructions on exchanging shares, and fractional shares will be rounded up. BiomX focuses on developing natural and engineered phage therapies to target harmful bacteria for chronic diseases. Forward-looking statements in this press release are based on current beliefs and expectations, subject to uncertainties and risks described in BiomX’s filings with the SEC. For more information, visit www.sec.gov.

Read more at GlobeNewswire: BiomX Inc. Announces 1-for-19 Reverse Stock Split